Why NPN Applications Fail: NHPD Submission Mistakes Under Canada's Natural Health Products Regulations

Most manufacturers filing their first NPN application assume the hard part is formulating the product. It isn’t. The hard part is assembling an evidence package that actually matches what the Natural and Non-prescription Health Products Directorate (NNHPD) expects — and understanding that “what it expects” is spread across dozens of guidance documents, compendial monographs, and policy notices that don’t always speak clearly with each other.

Canada has issued Product Licences for more than 100,000 natural health products since the Natural Health Products Regulations (NHPR, SOR/2003-196) came into force in January 2004. That’s a lot of successful applications. But behind that number is a filing history littered with deficiency letters, re-submissions, and products stuck in limbo for years because the initial dossier missed something that, in hindsight, was clearly documented in Health Canada guidance.

The mistakes that cause delays aren’t usually mysterious — they’re predictable, and most of them happen before a single form gets filled out.

Misassigning the Evidence Class Is More Common Than You’d Think

The NHPR establishes three evidence classes for product licence applications, and the one you choose determines your entire submission strategy — including what evidence you need to gather, how long review will take, and how much flexibility you have with your health claims.

• Class I (compendial): The ingredient and proposed use appear in an accepted reference, such as one of Health Canada’s published monographs. Review target is 60 business days.
• Class II (non-compendial, established safety and efficacy): The ingredient isn’t covered by a monograph, but there’s adequate peer-reviewed evidence for both safety and the proposed indication. Review target is 180 calendar days.
• Class III (non-compendial, traditional use): Safety is established through at least 50 years of traditional use evidence, with a minimum of 15 years within a recognized Western herbal, Ayurvedic, Traditional Chinese Medicine, or other accepted tradition. Review target is 300 calendar days.

The mistake I see most often: applicants assume that because a monograph exists for their ingredient, they automatically qualify for Class I treatment. That’s only true if your proposed use — including the dosage form, dose range, target population, and health claim — falls within the scope of what the monograph actually covers. Echinacea, for instance, is represented in Health Canada’s compendium, but the monograph distinguishes between whole plant preparations and specific extracts, and between adult and pediatric dosing. File outside those parameters and you’re no longer Class I, regardless of how confident you feel at the time.

The consequence of a misclassification isn’t a flat rejection. It’s a deficiency letter that asks you to justify your class assignment, which pauses your review clock and forces a re-submission cycle that can add months — sometimes the better part of a year — to the process.

Where Evidence Packages Consistently Fall Apart

Assuming you’ve correctly identified your evidence class, the next failure point is the evidence itself — specifically, how it maps to your exact product and health claim.

For Class I applications, compendial alignment has to be exact. If your product contains 400 mg of a specific extract standardized to a particular marker compound, and the monograph specifies a different standardization or a different plant part, you need to address that explicitly. Either amend your formulation to fit the monograph, or prepare a reasoned argument for why your formulation is substantially equivalent. Most first-time applicants skip this step, then wonder why a “straightforward” compendial submission came back with a deficiency.

For Class II applications, the evidentiary bar is higher than most expect. Health Canada’s published guidance on evidence for marketed health claims requires peer-reviewed clinical studies that are, wherever possible, randomized, double-blinded, and placebo-controlled. The study population should be reasonably representative of your intended consumer, the tested dose should be consistent with your proposed product, and statistical significance must be demonstrated. A p-value of less than 0.05 is a floor, not a ceiling — reviewers look at effect size and clinical relevance too.

Traditional use evidence — the kind that underpins Class III submissions — has its own trap. Many applicants confuse “historical sales” documentation with “traditional use” documentation under the NHPR. A stack of sales records from the past decade, or even anecdotal testimonials, won’t satisfy Health Canada’s requirements. You need primary ethnobotanical sources, recognized traditional medicine pharmacopoeias, or peer-reviewed historical texts demonstrating both the duration and the nature of use across an accepted tradition.

The GMP Evidence Gap That Stalls More Applications Than Any Other Issue

This one surprises clients most. Even when a product formulation is solid and the evidence package is well-assembled, an application won’t progress if you can’t demonstrate that the manufacturing site holds a valid Site Licence issued by Health Canada — or one from a foreign authority that Health Canada formally recognizes.

Under the NHPR, every NHP sold in Canada must be manufactured at a licensed site. The Site Licence number must appear in your Product Licence Application, the licence must cover the specific dosage form being manufactured, and it must be current at time of submission — not expired, not under suspension, not due for renewal in two weeks.

Where applicants get tripped up: they’re sourcing from a third-party contract manufacturer and assume the CMO handles all of this. Sometimes CMOs do stay on top of their own licencing — but the responsibility for verifying Site Licence status, confirming it covers your specific dosage form, and ensuring currency at submission sits with the product licence applicant, not the contract site.

I’ve reviewed dossiers where the Site Licence was entirely legitimate but covered tablet manufacturing, not capsules. That’s a deficiency. I’ve seen foreign facility certificates from reputable regulatory authorities that Health Canada hadn’t formally recognized for the relevant dosage form category at the time of filing. Another deficiency. Neither of these errors reflects badly on the manufacturer’s quality — but both stall the review clock, and both were completely avoidable with a 20-minute verification step before submission.

Five Specific Details That Trigger Deficiency Letters

Beyond the structural issues above, there are recurring technical details that show up in deficiency letters across otherwise sound applications:

1. Vague quantity-per-dosage-unit statements. “Each capsule contains a proprietary blend of botanical extracts” is not acceptable under the NHPR. Medicinal ingredient quantity must be stated per dosage unit, with the proper standardization marker identified where applicable. There’s no flexibility here.

2. Unapproved health claim language. Health Canada publishes specific wording for permitted claims in its compendium and guidance documents. Paraphrasing an approved claim — even slightly — can trigger a deficiency request. “Supports healthy immune function” and “helps maintain a healthy immune system” are not interchangeable in NNHPD’s view. Pull the exact language from the applicable monograph or guidance document and use it verbatim.

3. Missing cautionary statements for specific populations. Products containing iron must carry the specific overdose warning and “Keep out of reach of children” statement mandated by Health Canada. Products with botanicals documented to interact with common medications must include those interaction cautions in the Risk Information section. Reviewers cross-reference these against published tables — omissions are caught consistently.

4. Non-medicinal ingredient gaps. Every non-medicinal ingredient must be identified by its proper name and function. For some excipients — particularly novel ones or those present at concentrations above typical use levels — a brief safety justification is expected. Applicants who base their non-medicinal ingredient lists on a competitor’s NPN certificate are often working from outdated information and introduce avoidable deficiencies.

5. Incorrect dosage regimen statements. This is especially common for products with separate adult and pediatric doses. The application must specify dosage instructions for each population with age thresholds stated explicitly — “Adults 18 years and older: 2 capsules daily” rather than a catch-all “Adults: 2 capsules daily.” The distinction matters for review and for the eventual product label.

What a Clean First Submission Actually Looks Like

Applications that move through Health Canada review without deficiency letters share a few consistent features. They demonstrate in the Cover Letter exactly which evidence class is being claimed and precisely why. They include a structured evidence summary that maps each piece of evidence to each health claim being made. And they flag any areas of potential concern proactively — with an explanation — rather than hoping reviewers don’t find the gaps on their own.

Proactive disclosure is something experienced regulatory consultants use routinely and first-time applicants almost never do. If your clinical study used a slightly different extract standardization than your final formulation, say so upfront and explain why the evidence still supports your claim. Reviewers respond to transparency. That approach works far better than hoping an inconsistency goes unnoticed.

Before finalizing any NPN submission, have someone who wasn’t involved in drafting it do a line-by-line comparison against the applicable compendial monograph or evidence requirements — and against Health Canada’s current Product Licence Application form guidance. Most deficiencies are visible at that stage, if someone’s actually looking for them.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• Ingredient Identity and Raw Material Testing for NHP Submissions — Qalitex Laboratories provides ISO 17025-accredited testing and Certificates of Analysis to support Health Canada product licence dossiers.
• Natural and Cosmetic Product Regulatory Compliance for the EU Market — Care Europe helps Canadian brands navigate EU 1223/2009 and REACH requirements for natural products entering European markets.